{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:00:56Z","timestamp":1775145656742,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Photodiagnosis and Photodynamic Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.pdpdt.2025.105322","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:33:26Z","timestamp":1766018006000},"page":"105322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world data of verteporfin-related ocular adverse events: A disproportionality analysis"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3215-590X","authenticated-orcid":false,"given":"Nesrin","family":"Caglayan Duman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5787-3879","authenticated-orcid":false,"given":"Aslihan","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pdpdt.2025.105322_bib0001","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002030","article-title":"Photodynamic therapy for neovascular age-related macular degeneration","author":"Wormald","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.pdpdt.2025.105322_bib0002","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s12886-025-04249-8","article-title":"Comparative efficacy of photodynamic therapy (PDT), ranibizumab, aflibercept monotherapy, and combination therapies for polypoidal choroidal vasculopathy: a network meta-analysis of randomized controlled trials","volume":"25","author":"Quiroz-Reyes","year":"2025","journal-title":"BMC. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2025.105322_bib0003","article-title":"Two-year treatment outcome of photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy","author":"Kamimura","year":"2025","journal-title":"Photodiagnosis. Photodyn. Ther."},{"key":"10.1016\/j.pdpdt.2025.105322_bib0004","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2147\/OPTH.S464371","article-title":"Verteporfin photodynamic therapy for the treatment of chorioretinal conditions: a narrative review","volume":"18","author":"Garg","year":"2024","journal-title":"Clin. Ophthalmol."},{"issue":"2","key":"10.1016\/j.pdpdt.2025.105322_bib0005","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10103-008-0539-1","article-title":"Photophysics and photochemistry of photodynamic therapy: fundamental aspects","volume":"24","author":"Plaetzer","year":"2009","journal-title":"Lasers. Med. Sci."},{"issue":"2","key":"10.1016\/j.pdpdt.2025.105322_bib0006","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/eye.2015.251","article-title":"Photodynamic therapy: current role in the treatment of chorioretinal conditions","volume":"30","author":"Newman","year":"2016","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.pdpdt.2025.105322_bib0007","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.2147\/IJN.S532074","article-title":"Nanomedicine-based ophthalmic drug delivery systems for the treatment of ocular diseases","volume":"20","author":"Lin","year":"2025","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.pdpdt.2025.105322_bib0008","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10456-008-9106-4","article-title":"Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne), in the CAM model","volume":"11","author":"Debefve","year":"2008","journal-title":"Angiogenesis."},{"key":"10.1016\/j.pdpdt.2025.105322_bib0009","series-title":"StatPearls [Internet]","article-title":"Adverse drug reactions. 2024 Jan 10","author":"Kommu","year":"2025"},{"key":"10.1016\/j.pdpdt.2025.105322_bib0010","unstructured":"Food and Drug Administration. FDA adverse event reporting system (FAERS) public dashboard. https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard (accessed 6 January 2025)."},{"key":"10.1016\/j.pdpdt.2025.105322_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241285929","article-title":"Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database","volume":"15","author":"Wu","year":"2024","journal-title":"Ther. Adv. Drug Saf."},{"issue":"8","key":"10.1016\/j.pdpdt.2025.105322_bib0012","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40264-023-01325-0","article-title":"Use of electronic health record data for drug safety signal identification: a scoping review","volume":"46","author":"Davis","year":"2023","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.pdpdt.2025.105322_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS. One"},{"key":"10.1016\/j.pdpdt.2025.105322_bib0014","unstructured":"OpenVigil. https:\/\/openvigil.sourceforge.net\/(accessed 2 January 2025)."},{"key":"10.1016\/j.pdpdt.2025.105322_bib0015","article-title":"A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor","volume":"15","author":"Pan","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.pdpdt.2025.105322_bib0016","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","volume":"117","year":"1999","journal-title":"Arch. Ophthalmol."},{"issue":"2","key":"10.1016\/j.pdpdt.2025.105322_bib0017","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00002512-200016020-00005","article-title":"Verteporfin","volume":"16","author":"Scott","year":"2000","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.pdpdt.2025.105322_bib0018","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","year":"2001","journal-title":"Am. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.pdpdt.2025.105322_bib0019","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","article-title":"Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial\u2013VIP report no. 1","volume":"108","author":"in","year":"2001","journal-title":"Ophthalmology."},{"key":"10.1016\/j.pdpdt.2025.105322_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2025.104576","article-title":"Long-term retrospective analysis of retinal pigment epithelium atrophy and secondary hyperplasia following verteporfin photodynamic therapy","volume":"53","author":"Hsu","year":"2025","journal-title":"Photodiagnosis. Photodyn. Ther."},{"issue":"3","key":"10.1016\/j.pdpdt.2025.105322_bib0021","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00002512-200421030-00005","article-title":"Spotlight on verteporfin in subfoveal choroidal neovascularisation","volume":"21","author":"Keam","year":"2004","journal-title":"Drugs Aging"},{"issue":"11","key":"10.1016\/j.pdpdt.2025.105322_bib0022","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv. Ther."},{"issue":"7","key":"10.1016\/j.pdpdt.2025.105322_bib0023","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s40123-024-00952-9","article-title":"Perspectives and update on the global shortage of Verteporfin (Visudyne\u00ae)","volume":"13","author":"Sirks","year":"2024","journal-title":"Ophthalmol. Ther."},{"key":"10.1016\/j.pdpdt.2025.105322_bib0024","unstructured":"European Medicines Agency. Visudyne - supply shortage. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/shortages\/visudyne (accessed 28 September 2025)."},{"key":"10.1016\/j.pdpdt.2025.105322_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2025.104654","article-title":"Photodynamic therapy in ocular oncology: a bibliometric analysis (1987-2024)","volume":"54","author":"T\u00fcrko\u011flu","year":"2025","journal-title":"Photodiagnosis. Photodyn. Ther."},{"issue":"4","key":"10.1016\/j.pdpdt.2025.105322_bib0026","doi-asserted-by":"crossref","first-page":"547","DOI":"10.18502\/jovr.v15i4.7793","article-title":"Photodynamic therapy in ocular oncology","volume":"15","author":"Mazloumi","year":"2020","journal-title":"J. Ophthalmic. Vis. Res."},{"issue":"1","key":"10.1016\/j.pdpdt.2025.105322_bib0027","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2005.09.002","article-title":"Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration","volume":"113","author":"Augustin","year":"2006","journal-title":"Ophthalmology."},{"key":"10.1016\/j.pdpdt.2025.105322_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2025.104746","article-title":"Two-year treatment outcome of photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy","volume":"55","author":"Uemura","year":"2025","journal-title":"Photodiagnosis. Photodyn. Ther."}],"container-title":["Photodiagnosis and Photodynamic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1572100025008531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1572100025008531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:20:14Z","timestamp":1775143214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1572100025008531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":28,"alternative-id":["S1572100025008531"],"URL":"https:\/\/doi.org\/10.1016\/j.pdpdt.2025.105322","relation":{},"ISSN":["1572-1000"],"issn-type":[{"value":"1572-1000","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world data of verteporfin-related ocular adverse events: A disproportionality analysis","name":"articletitle","label":"Article Title"},{"value":"Photodiagnosis and Photodynamic Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pdpdt.2025.105322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105322"}}